7results about How to "Reduce degeneration" patented technology

The invention proves that the isosakuranetin can inhibit the generation of osteoclasts and the functions of the osteoclasts in vitro, protect the bone microstructure of subchondral bones of an OA (osteoarthritis) mouse, relieve the degeneration of articular cartilage of the OA mouse, inhibit the generation of abnormal blood vessels in subchondral marrow cavities in the progress of the OA, and inhibit the osteoclasts in the osteoclasts. The invention proves that the isosakuranetin has a treatment effect on the osteoarthritis for the first time, and discloses an action mechanism of the isosakuranetin.

The utility model belongs to the technical field of medical instruments, and relates to a joint implant for the orthopedics department. The joint implant is used for joint bone cartilage injury and defect repair and comprises a joint implant base body with a porous titanium structure and a top solid self-lubricating film. The joint implant base includes a top region, an upper region, and a lower region. The top area is matched with the outer contour face of the human body bone and is of a dense mirror face structure, the surface of the top area is plated with a solid self-lubricating film, abrasion to the opposite-side cartilage can be reduced to a large extent, and degeneration of the opposite-side cartilage is reduced. The side faces of the top area and the upper area of the joint implant base body make contact with subchondral bones and cancellous bones of the human body, and the lower area of the joint implant base body makes contact with the cancellous bones of the human body. The aperture and porosity of the joint implant base body extend from the upper area to the lower area, are increased in a gradient manner, are matched with the mechanical properties of human bones, and are beneficial to initial stability, early-stage rapid bone ingrowth and long-term stability.

This invention discloses the application of a Cav3.2 inhibitor in the preparation of a drug for treating intervertebral disc degeneration. Z944 can block the activation level of Cav3.2 in nucleus pulposus cells, effectively alleviating lipid metabolism disorders and cellular biological behavior disorders induced by abnormal mechanical stress, and ultimately reducing intervertebral disc degeneration. This demonstrates that Z944 is a drug with clinical application potential, which can be used to alleviate the pain and burden of patients with low back pain and improve their quality of life.

The application discloses a kind of nanocomposite hydrogel for treating osteoarthritis and its preparation method and application, the nanocomposite hydrogel includes cerium dioxide nanoparticles, the cerium dioxide nanoparticles are modified with hyaluronic acid;Ergothioneine is loaded on hyaluronic acid modified cerium dioxide nanoparticles to form nanocomposite EGT-CeO2@HA;And temperature-sensitive hydrogel carrier, the nanocomposite EGT-CeO2@HA is uniformly dispersed in the temperature-sensitive hydrogel carrier.This composite hydrogel can activate ATF4-dependent pro-survival autophagy pathway, reduce cartilage cell inflammatory damage, and improve cartilage degeneration.

This invention belongs to the field of biomedical technology and relates to the application of PAX8 gene inhibitors in the preparation of drugs for treating optic nerve degeneration. The PAX8 gene inhibitor is a shRNA that targets and inhibits the PAX8 gene or a vector expressing a shRNA that targets and inhibits the PAX8 gene. The vector uses the astrocyte-specific promoter gfabc1d. Experiments have demonstrated that by specifically inhibiting PAX8 expression in astrocytes, axoplasmic transport obstruction in the optic nerve is relieved, optic nerve degeneration is alleviated, and a new gene therapy strategy is provided for the protective treatment of optic nerve degeneration in glaucoma.

The utility model discloses a cervical vertebra bolster, which achieves the purposes of effectively correcting the physiological curve of the cervical vertebra of a patient, relieving the degeneration of cervical intervertebral disc and increasing the stability of the cervical vertebra, and comprises a pitching pillow, the pitching pillow comprises an arc-shaped head pillow and an arc-shaped neck pillow which are smoothly connected through a smooth concave cambered surface to form a B-shaped pillow surface conforming to the physiological curve of the head of a human body, square side pillows with the same height are arranged on the two sides of the pitching pillow respectively, the square side pillows are higher than the neck pillow, and the neck pillow is higher than the head pillow; a head positioning pillow is movably erected on the headrest, the radian of the head positioning pillow is the same as that of the headrest, and an arc-shaped groove is formed in the upper portion of the head positioning pillow.

The invention discloses an application of dihydroartemisinin in preparation of an antioxidant drug for hemophilia arthropathy, and particularly relates to an application of DHA (docosahexaenoic acid) in delaying cartilage cell degeneration by inhibiting ROS (reactive oxygen species) level in cartilage cells in the presence of blood. In-experience verification shows that the DHA delays HA degeneration by delaying the ROS level in cartilage cells. Therefore, DHA has a good application prospect in treatment of hemophilia arthropathy. The extensive use of current modern hematology nursing does not provide considerable protection for the development of prevention of HA. The total knee arthroplasty can relieve pain of an end-stage HA patient and restore joint function. According to the invention, the oxidation resistance of the cartilage cells can be well improved, so that the progress of HA (hemagglutinin) is delayed.